PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

BACKGROUND: The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP inhibitor, is being tested in clinical trials. However, veliparib only showed a moderate anticancer effect, and combination thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Linglong, Liu, Youhong, Peng, Yuchong, Peng, Yongbo, Yu, Xiaohui, Gao, Yingxue, Yuan, Bowen, Zhu, Qianling, Cao, Tuoyu, He, Leye, Gong, Zhicheng, Sun, Lunquan, Fan, Xuegong, Li, Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048811/
https://www.ncbi.nlm.nih.gov/pubmed/30012171
http://dx.doi.org/10.1186/s13046-018-0810-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048811/
https://www.ncbi.nlm.nih.gov/pubmed/30012171
http://dx.doi.org/10.1186/s13046-018-0810-7

Ejemplares similares